Skip to main content

Table 2 Outcome of 63 patients with BSIs due to Candida parapsilosis complex considered in this study

From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex

Characteristics

30-day outcome

Survival (n = 46)

Death (n = 17)

P valuea

Age (years), median (IQR)b

62 (31–75)

76 (63–78)

0.046

Male sex, n (%)

24 (52)

11 (65)

0.374

Ward

 Internal Medicine, n (%)

21 (46)

4 (24)

0.033

 Surgery, n (%)

14 (30)

3 (18)

 

 Intensive Care Unit, n (%)

11 (24)

10 (59)

Comorbidities, n (%)

40(87)

17(100)

0.117

 Chronic pulmonary diseases, n (%)c

5(11)

4 (24)

0.235

 Haematological malignancy, n (%)

1 (2)

0 (0)

0.540

 Cardiovascular diseases, n (%)d

15 (33)

12(71)

0.006

 Neurological diseases, n (%)e

9 (20)

1(6)

0.263

 Gastrointestinal diseases, n (%)f

16 (35)

5 (29)

0.688

 Diabetes mellitus, n (%)

4 (9)

4 (24)

0.195

 Solid tumors, n (%)

9 (20)

6 (35)

0.193

 Chronic renal failure, n (%)

5 (11)

2 (12)

1.000

Previous surgery (<30 days), n (%)

23(50)

9(53)

0.835

 Gastrointestinal surgery, n (%)

5(11)

3(18)

0.671

 Cardiovascular surgery, n (%)

7(15)

6(35)

0.080

 Other surgery, n (%)g

11(24)

1 (6)

0.154

Central venous catheter, n (%)

41(89)

15 (88)

0.920

 BSI CVC-related, n (%)

25 (61)

11 (73)

0.460

 Early central venous catheter removal, n (%)h

41 (100)

11 (73)

<0.0001

Other devices, n (%)i

40 (87)

17(100)

0.178

Previous invasive procedures (<72 h), n (%)j

9 (20)

7 (41)

0.080

Parenteral nutrition, n (%)

29 (63)

14 (82)

0.143

Immunosuppressive therapy, n (%)k

13(28)

5(29)

0.920

Neutropenia, n (%)

3 (7)

1 (6)

1.000

Septic shock, n (%)

1(2)

1(6)

0.470

Prior antibiotic therapy, n (%)

42 (91)

16 (94)

0.713

Previous antifungal therapy, n (%)

4 (9)

1 (6)

0.713

Concomitant bacteriemia, n (%)

12(26)

3(18)

0.487

Other coinfections, n (%)l

28 (61)

11(65)

0.780

Appropriate antifungal therapym

30 (65)

8 (47)

0.190

 Primary azole therapy

32 (70)

9 (53)

0.219

 Primary echinocandin therapy

5 (11)

2 (12)

1.000

 Primary polyene therapy

1 (2)

0 (0)

1.000

 None

8 (17)

6 (35)

0.129

  1. aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables
  2. b IQR, Interquartile range
  3. cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
  4. dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
  5. eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
  6. fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
  7. gOther surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
  8. h Early CVC removal was considered occurring within 48 h from blood cultures drawing
  9. i Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
  10. j Previous invasive procedures include endoscopy and positioning of any device
  11. kImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
  12. l Other coinfections include bacterial and/or fungal infections in sites other than blood
  13. mAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started within 72 h the first blood culture performed